A Long-Term Follow-Up Observational Study To Evaluate Safety In Subjects Who Have Received A Gene-Modified Regulatory T Cell (Treg) Therapeutic

Overview

About this study

To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Subject was previously administered at least 1 dose of a Sonoma Biotherapeutics, Inc. gene-modified Treg therapeutic in a prior parent treatment protocol.
* Subject understands the purpose and risks of the study and is willing to provide written informed consent.
* Subject is willing to comply with all study procedures for the follow-up period.

Exclusion Criteria:

* Participation in the study is not in the subject's best interest, in the opinion of the Investigator

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 01/26/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Fawad Aslam

Open for enrollment

Contact information:

Fawad Aslam

aslam.fawad@mayo.edu

More information

Publications

Publications are currently not available